In one paragraphArticle in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Xiao-Hui Chen *Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).ORCID 0000-0002-8421-0050 Jing-Rong Lin *Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).ORCID 0000-0002-0218-7214 Ze-Bei Zhang *Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).ORCID 0000-0001-5260-9254 Jia-Qi LiDepartment of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).
Dong-Rui ChenDepartment of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).
Yong-Hua ZhaiDepartment of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).
Lian XuDepartment of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).ORCID 0000-0002-6319-4661 Tomasz GuzikDepartment of Medicine, Jagiellonian University, Collegium Medicum, Kraków, Poland (T.G.).ORCID 0000-0002-5039-7849 Ping-Jin GaoDepartment of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (X.-H.C., J.-R.L., Z.-B.Z., J.-Q.L., D.-R.C., Y.-H.Z., L.X., P.-J.G.).ORCID 0000-0002-7750-3314 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundInnate and adaptive immune cells play important roles in the pathogenesis of hypertension. B cells play a crucial role in mammalian adaptive immunity via processing antigens and producing antibodies. However, whether B cells and immunoglobulins are involved in regulating blood pressure in hypertension remains unclear. We aimed to reveal the protective role and the potential immunoregulatory mechanisms of B1a cells in hypertension.
methodsWild-type and CD19 knockout (CD19
resultsWe found that the frequency of B1a cells was reduced in the blood and peritoneal cavity in wild-type mice after Ang II infusion. We showed that CD19
conclusionsOur data demonstrated that B1a cells play a protective role in the development of hypertension via producing natural IgM and inhibiting IFNγ production by CD4+T cells.
Indexed as
B-Lymphocyte SubsetsCD4-Positive T-LymphocytesHypertensionImmunoglobulin MInterferon-gammaAdoptive TransferAngiotensin IIAnimalsAntigens, CD19Blood PressureCells, CulturedMaleMiceMice, Inbred C57BLMice, KnockoutAngiotensin IIAntigens, CD19CD19 antigen, mouseIFNG protein, mouseImmunoglobulin MInterferon-gammaB-lymphocyte subsetsCD4-positive T-lymphocyteshypertensionimmunoglobulin Minterferon-gamma
Identifiers
PMID42411280
PMCPMC13418875
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390